–
The stem cell developer could be acquired at a company value of hundreds of millions of dollars.
–
Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
Stem cell therapies developer Gamida-Cell Ltd. has received an acquisition offer from an international pharma company, Novartis AG (NYSE:NVS; LSE: NOV; SWX: NOVZ).
Elbit Medical Technologies, which has a 30.8 percent share in Gamida, said in a notification to the Tel Aviv Stock Exchange (TASE) by Clal Biotechnology Industries Ltd. (TASE: CBI) that Gamida-Cell will be acquired at a potential company value of several hundred million dollars in a down payment, milestone payments, and royalties on future sales of commercialized products.
–
